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Introduction
Iron deficiency is the most common cause of anemia
worldwide. Chronic blood loss is one of the common
causes of iron deficiency anemia (IDA). Occult bleeding
from the gastrointestinal (GI) tract is usually thought
to be the leading cause of IDA in adults.1 A population-
based cohort study proved that GI malignancy was
significantly more common in those with iron defi-
ciency than in those with normal serum iron satura-
tion and hemoglobin levels.2 Our previous study3 and
others4–6 showed that the prevalence of GI malig-
nancy in patients with IDA ranged from 10% to 17%.
Tan et al7 and Sworczak et al8 reported that IDA was
one of the predictive factors of colorectal cancer and
small intestinal cancer. Thus, the correlation of IDA
and malignancy is well known and should be kept in
mind in clinical practice. In our previous prospective
study, we demonstrated the prevalence of GI malignancy
in IDA patients.3 In order to define the prevalence and
the clinical implications of IDA in colorectal cancer
patients, a retrospective study was conducted.
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Methods
From the database of the hospital computer system,
we searched the discharge notes for patients who had 
a diagnosis of proven carcinoma of the colon in 2003–
2005 in Taipei Veterans General Hospital. Patients with
pathology-proven colon carcinoma and with adequate
recorded data to be evaluated were enrolled into our
study. Basic data such as age, gender, tumor site and
size, tumor stage, tumor pathology, lymph node involve-
ment and metastasis were recorded. Clinical symptoms
and laboratory data including anorexia, nausea, vom-
iting, constipation, diarrhea, abdominal pain, change of
bowel habit, body weight loss, tarry stool, small cal-
iber of stool, serum ferritin, serum iron (SI), total iron
binding capacity (TIBC), complete blood count (CBC),
blood urea nitrogen (BUN), creatinine, alanine amino-
transferase (ALT), aspartate aminotransferase (AST),
carcinoembryonic antigen (CEA), lactate dehydroge-
nase (LDH), stool occult blood, colonoscopy and
barium enema findings were recorded as well.
Two methods were used to represent the tumor size:
the greatest diameter and the area calculated using the
2 greatest dimensions of the tumor. Tumor site was
recorded and divided into right colon and non-right
colon tumors. Right colon tumors included tumors in
the cecum, ascending colon or the hepatic flexure; non-
right colon tumor included tumors in the remaining sites
of the colon. Tumor staging was determined according
to the AJCC TNM system in colorectal cancer.
Anemia was defined as hemoglobin < 12 g/dL. We
compared the prevalence of anemia with elevations of
CEA and LDH in patients with colon cancer, and deter-
mined the relationships between anemia and other
parameters.
We divided the patients into 2 groups: with or
without anemia. The χ2 test or Fisher’s exact test was
used to compare the hemoglobin concentration with
gender, cancer stage and clinical symptoms; Mann-
Whitney rank sum test or Student’s t test was used 
to compare hemoglobin with the continuous variables.
If the result was significant (p < 0.05), multivariate lo-
gistic regression was used to find the real correlating
factors.
Serum ferritin was recorded in 25 of the 101 patients.
We compared the relationship of ferritin level with
other variables in order to find out the risk factors of
lower serum ferritin.
Results
General data in 101 patients with colon
carcinoma
A total of 101 patients were enrolled. Their mean age
was 65.3 years; 56 of them were male. All had adeno-
carcinoma except for 1 who had poorly differentiated
carcinoma. The most frequent site of tumor occur-
rence was the rectum (34 patients), followed by the
sigmoid colon (32 patients) and then the ascending
colon (10 patients). Three patients had 2 different
occurring sites. Fifty-one patients (51%) had anemia.
Two groups were distinguished according to the pres-
ence of anemia or not. Table 1 shows the mean and SD
of the variables in these 2 groups of patients. Twenty-
three of the 101 patients had cancer of the right colon,
17 (74%) of them had anemia. Seventy-eight patients
had non-right colon cancer, 34 (44%) of them had
anemia. The rate of anemia was higher in the right colon
cancer than in the non-right colon cancer patients.
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Table 1. Means of variables in the anemia and non-anemia groups in 101 patients with colon carcinoma*
Anemia group Non-anemia group Total
Age (yr) 62.9 ± 13.7 (51) 67.8 ± 13.9 (50) 65.3 ± 14.0 (101)
Maximum tumor diameter (cm) 5.28 ± 2.17 (51) 3.93 ± 1.83 (48) 4.62 ± 2.12 (99)
Serum ferritin (µg/L) 80.4 ± 208.6 (17) 148.3 ± 138.9 (8) 102.1 ± 188.9 (25)
Transferrin saturation (%) 24.5 ± 14.6 (14) 33.1 ± 7.2 (8) 27.7 ± 12.9 (22)
Hemoglobin (g/dL) 9.98 ± 1.43 (51) 13.60 ± 1.12 (50) 11.80 ± 2.22 (101)
Hematocrit (%) 30.2 ± 3.9 (51) 41.0 ± 7.7 (50) 35.5 ± 8.1 (101)
WBC (× 109/L) 8.2 ± 3.5 (51) 7.5 ± 3.4 (50) 7.8 ± 3.5 (101)
Platelets (× 109/L) 299 ± 114 (51) 258 ± 93 (50) 279 ± 106 (101)
LDH (U/L) 292 ± 274 (50) 296 ± 471 (43) 294 ± 375 (93)
Creatinine (mg/L) 1.2 ± 1.2 (51) 1.0 ± 0.3 (50) 1.1 ± 0.9 (101)
ALT (U/L) 17.0 ± 19.1 (50) 22.4 ± 23.2 (49) 19.7 ± 21.3 (99)
CEA (U/L) 82 ± 293 (48) 234 ± 772 (47) 157 ± 583 (95)
*Data are presented as mean ± standard deviation (number of patients examined). WBC = white blood cell count; LDH = lactate dehydrogenase; ALT = alanine
aminotransferase; CEA = carcinoembryonic antigen.
CEA and LDH were measured in 95 and 93 patients,
respectively. CEA was high (>6.0U/L) in 45% (43/95)
of the patients, and LDH was high (> 213 U/L) in
46% (43/93) of the patients.
Relationships between anemia and other
variables
Different variables were compared in the 2 groups of
patients (Table 2). Pearson’s χ2 test showed that female
gender, right colon tumor and tumor diameter > 3 cm
were significantly associated with anemia (p < 0.0005,
=0.005 and =0.026, respectively). Mann-Whitney rank
sum test and Student’s t test showed that anemia was
related with the diameter and the area of the tumor
(p = 0.001 and 0.002, respectively). None of the clini-
cal symptoms was found to have any significant rela-
tionship with anemia. Concerning laboratory data,
hematocrit, red blood cell number, mean corpuscular
volume, serum ferritin, transferrin saturation (SI/TIBC)
and platelet count were found to be related with anemia
(p < 0.0005, < 0.0005, < 0.0005, = 0.006, = 0.049 and
= 0.018, respectively), whereas LDH, CEA, CA-125
and CA-19-9 were not correlated with anemia. Multi-
variate logistic regression showed that female gender,
tumor diameter > 3 cm, and right colon tumor were
related with anemia (p<0.0005,=0.05,=0.029 respec-
tively, and OR = 6.711, 3.699 and 3.907, respectively).
Percentage of low serum ferritin and low
transferrin saturation in patients with 
colon cancer
Serum ferritin was measured in 25 of the 101 patients,
15 (60%) of whom had low serum ferritin (< 40 µg/L).
Transferrin saturation was measured in 22 of the
patients; only 3 (14%) had less than 15%, and 5 (23%)
had less than 16%.
Discussion
The association of iron deficiency anemia and GI tract
malignancy has been well known in recent years. In 
a patient with unknown cause of IDA, a full survey 
of the GI series to rule out the possibility of malig-
nancy is suggested. In our previous study, 12.2% of
IDA patients were found to have malignancy,3 there-
fore, iron deficiency anemia should be regarded as one
of the predictors of GI malignancy. In the present ret-
rospective study, in contrast to our previous study,
patients with confirmed carcinoma of the colon and
rectum were analyzed in order to find out the preva-
lence of anemia, and the relationship of anemia with
different variables in them.
Anemia was found in about half (51%) of the patients
with carcinoma of the colon and rectum. This rate was
slightly higher than those with elevation of CEA (45%)
and LDH (46%). Furthermore, in 23 patients with right
colon cancer, the anemia rate was even higher (74%),
although it was slightly lower than that reported by
Kanellos et al (87.2%).9 Even in 78 patients with non-
right colon cancer, the prevalence of anemia was not
low (44%). Thus, in spite of its non-specificity, anemia
seems to be a good marker in patients with carcinoma
of the colon.
Female gender, tumor maximum diameter > 3 cm
and right colon cancer were found to be related with
anemia. It is easy to understand why female gender 
is more prone to have IDA than male. Females have 
a greater opportunity to lose iron during the child-
bearing ages; this contributes to the higher rate of
IDA in the general population as well as in patients
with colon cancer. Thus, in a female patient with IDA,
many factors other than GI tract malignancy should
be considered. In contrast, in a male patient with IDA,
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Table 2. Relationship between anemia and other variables
p value
Pearson’s χ2 Mann-Whitney rank sum test Paired t test MLR
Gender < 0.0005 < 0.0005
Right colon tumor < 0.005 0.029
Tumor diameter > 3 cm 0.026 0.001 0.05
Tumor area 0.002
Hematocrit < 0.0005
RBC number < 0.0005
MCV < 0.0005
Serum ferritin 0.006
Transferrin saturation 0.049
Platelet number 0.018
MLR = multivariate logistic regression; RBC = red blood cell; MCV = mean corpuscular volume.
GI tract malignancy should be kept in mind unless
another definite cause has been found.
Anemia was found to be associated with greater
tumor diameter and with right colon cancer. In gen-
eral, greater tumor diameter means longer growth time
of the tumor, and right colon cancer usually causes
less chance of obstruction than non-right colon tumor,
and thus later discovery of the tumor. Both of these
factors explain why the longer the tumor exists, the
greater the chance anemia will occur. It also means
that although anemia is an important clinical manifes-
tation of colon cancer, it probably is not a very early
marker of colon cancer. However, it can still be a sign
for us to consider the possibility of GI malignancy when
a patient has an unknown cause of anemia.
In the present retrospective study, unfortunately,
transferrin saturation and serum ferritin were mea-
sured in only 22 and 25 patients, respectively. This
probably demonstrates the fact that clinicians do not
have the concept to check serum ferritin in a patient
with suspected colon cancer as they do not think it 
is important. Serum ferritin is closely related with
iron store. Low serum ferritin (< 40 µg/L) was found
in more than half (15/25, 60%) of the patients with
colon cancer. In general, low serum ferritin always
represents iron deficiency, although the cutoff point of
low serum ferritin was different in different reports.
On the other hand, if a patient has higher serum fer-
ritin, iron deficiency cannot be completely ruled out,
as serum ferritin is an acute-phase reactant; it can also
rise in malignancy,10 and thus can be falsely high even
in patients with iron deficiency but associated with
malignancy. As more than half of the patients detected
with colon cancer had iron deficiency, this shows that
the cause of anemia in colon cancer was mostly due to
iron deficiency, and was compatible with the presence
of chronic blood loss in patients with colon cancer.
Furthermore, platelet count was significantly higher
in the anemia group than in the non-anemia group
(p = 0.018, data not shown), which was also indirect
evidence to imply the presence of IDA, as thrombo-
cytosis is known to be one of the common signs of
IDA.11–14 From our previous study, we found that
12.2% of IDA patients had GI malignancy,3 and in the
present study, more than half of the patients with colo-
rectal cancer had anemia, thus, we concluded that IDA
was a common clinical manifestation in patients with
colorectal carcinoma.
In conclusion, low hemoglobin and serum ferritin
were commonly seen in patients with colorectal cancer.
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